Drug intelligence / Profile preview

RESTIF

Development stage: Unknown
Lead developer: Positif Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

**RESTIF** is a marketed oral cough syrup from Positif Life Sciences for productive cough associated with mucus retention and airway symptoms. The 100 mL syrup is reported to contain bromhexine, guaifenesin, menthol, and terbutaline: bromhexine acts as a mucolytic, guaifenesin promotes expectoration, menthol provides a cooling throat-soothing effect, and terbutaline is a beta-2 adrenergic receptor agonist that produces bronchodilation. It is a fixed-dose multi-ingredient pharmaceutical product rather than a single molecular entity.

Brand names: RESTIF
Other names: Restif Syrup

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on RESTIF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RESTIF.

Explore the full profile